Data · Analytics · Generative AI

Turning data into decisions — where it is hardest.

Turning data into decisions — and taking GenAI into production where it is hardest. Led by Julian Grijalba, Head of Data Insights & Competitiveness LATAM at Roche.

h4
here4data
20
years turning data into decisions
57+
countries across EMEA & LATAM
121
regulatory & market sources in a live GenAI system
23
person matrix team across 6 affiliates
Two decades across RocheKimberly-ClarkEveris (NTT Data)University of Texas at Austin

What we do

GenAI in production, not in a slide deck.

Most organizations pilot AI. The hard part — and the value — is running it live, governed, at scale, in regulated industries. That is the work.

GenAI & agentic AI in production

Moving multi-agent and RAG systems past the pilot into live, governed operation in regulated industries.

Multi-agent pharma-intelligence system across 8 countries / 121 regulatory & market sources at Roche (2026).

From reporting to business partnering

Repositioning analytics teams into strategic partners of GMs and the board.

Launched Roche’s Data Insights Network operating model (2026); eliminated 74% of regional reports at Kimberly-Clark (2023).

Data operating models & governance at scale

Single source of truth, KPI harmonization and data stewardship across many countries.

Core & Common KPI framework across 6 affiliates (2026); harmonized 78% of regional KPIs across 14 countries.

Competitive & market intelligence for pharma

Feeding disease-area and specialty-care intelligence into commercial and market-access strategy.

Rolling out Roche’s regional competitive-intelligence capability (2026).

Selected outcomes

Evidence, not adjectives.

37%
faster decision cycles from scalable analytics platforms (Kimberly-Clark, EMEA & LATAM)
74%
of regional reports eliminated into a single source of truth (LATAM)
121
regulatory & market sources feeding a live multi-agent GenAI system (Roche)
“The problem was never the data — it was the distance between the data and the decision. In pharma that distance has a name and a face: a patient who does or does not access a treatment depending on how well we use information.” — Julian Grijalba, Head of Data Insights & Competitiveness, LATAM at Roche